| Many routes to an antibody heavy-chain CDR3: necessary, yet insufficient, for specific binding S D’Angelo, F Ferrara, L Naranjo, MF Erasmus, P Hraber, ARM Bradbury Frontiers in immunology 9, 336672, 2018 | 95 | 2018 |
| Drug-like antibodies with high affinity, diversity and developability directly from next-generation antibody libraries AAR Teixeira, MF Erasmus, S D’Angelo, L Naranjo, F Ferrara, ... MAbs 13 (1), 1980942, 2021 | 26 | 2021 |
| A pandemic-enabled comparison of discovery platforms demonstrates a naïve antibody library can match the best immune-sourced antibodies F Ferrara, MF Erasmus, S D’Angelo, C Leal-Lopes, AA Teixeira, ... Nature communications 13 (1), 462, 2022 | 25 | 2022 |
| A single donor is sufficient to produce a highly functional in vitro antibody library MF Erasmus, S D’Angelo, F Ferrara, L Naranjo, AA Teixeira, R Buonpane, ... Communications Biology 4 (1), 350, 2021 | 22 | 2021 |
| Dynamic pre-BCR homodimers fine-tune autonomous survival signals in B cell precursor acute lymphoblastic leukemia MF Erasmus, K Matlawska-Wasowska, I Kinjyo, A Mahajan, SS Winter, ... Science signaling 9 (456), ra116-ra116, 2016 | 18 | 2016 |
| Allergen valency, dose, and FcεRI occupancy set thresholds for secretory responses to Pen a 1 and motivate design of hypoallergens A Mahajan, LA Youssef, C Cleyrat, R Grattan, SR Lucero, CP Mattison, ... The Journal of Immunology 198 (3), 1034-1046, 2017 | 17 | 2017 |
| Recombinant Antibodies against Mycolactone N Naranjo, F Ferrara, N Blanchard, C Demangel, S D’Angelo, ... Toxins 11 (346), 2019 | 10 | 2019 |
| Simultaneous affinity maturation and developability enhancement using natural liability-free CDRs AAR Teixeira, S D’Angelo, MF Erasmus, C Leal-Lopes, F Ferrara, ... MAbs 14 (1), 2115200, 2022 | 7 | 2022 |
| Rapid purification of billions of circulating CD19+ B cells directly from leukophoresis samples F Ferrara, M Kolnik, S D’Angelo, FM Erasmus, D Vorholt, ARM Bradbury New biotechnology 46, 14-21, 2018 | 7 | 2018 |
| Exploiting next-generation sequencing in antibody selections–a simple PCR method to recover binders F Ferrara, AA Teixeira, L Naranjo, MF Erasmus, S D’Angelo, ... MAbs 12 (1), 1701792, 2020 | 6 | 2020 |
| Insights into next generation sequencing guided antibody selection strategies MF Erasmus, F Ferrara, S D’Angelo, L Spector, C Leal-Lopes, AA Teixeira, ... Scientific reports 13 (1), 18370, 2023 | 3 | 2023 |
| Many routes to an antibody heavy-chain CDR3: necessary, yet insufficient, for specific binding. Front Immunol. 2018; 9: 395 S D'Angelo, F Ferrara, L Naranjo, MF Erasmus, P Hraber, ARM Bradbury | 2 | 2018 |
| Pandemic’s silver lining F Ferrara, S D’Angelo, MF Erasmus, AA Teixeira, C Leal-Lopes, ... MAbs 14 (1), 2133666, 2022 | 1 | 2022 |
| Characterization of the metal binding by the anti-sphingosine-1-phosphate antibody LT1002 MF Erasmus Sciences, 2012 | 1 | 2012 |
| Antibody libraries with maximized antibody developability characteristics ARM Bradbury, MF Erasmus, A Teixeira US Patent 11,920,258, 2024 | | 2024 |
| Author Correction: Insights into next generation sequencing guided antibody selection strategies MF Erasmus, F Ferrara, S D’Angelo, L Spector, C Leal-Lopes, AA Teixeira, ... Scientific reports 14, 2024 | | 2024 |
| Determining the affinities of high-affinity antibodies using KinExA and surface plasmon resonance MF Erasmus, M Dovner, F Ferrara, S D’Angelo, AA Teixeira, C Leal-Lopes, ... Mabs 15 (1), 2291209, 2023 | | 2023 |
| High throughput purification of monoclonal recombinant antibodies using a Protein-A coated membrane plate system C Leal-Lopes, S D’Angelo, MF Erasmus, AAR Teixeira, G Temples, ... New Biotechnology 77, 111-119, 2023 | | 2023 |
| A Novel Antibody-Drug Conjugate Directed Towards the Surrogate Light Chain of Malignantly-Transformed B-Cell Precursors Reverses Leukemic Progression in NSG Mice PM Gordon, J Ostergaard, LM Jonart, MF Erasmus, BS Wilson, SS Winter Blood 140 (Supplement 1), 9201-9202, 2022 | | 2022 |
| Spatial Stochastic Model of the Pre-B Cell Receptor R Kerketta, MF Erasmus, BS Wilson, ÁM Halász, JS Edwards IEEE/ACM transactions on computational biology and bioinformatics 20 (1 …, 2022 | | 2022 |
Cédric CleyratJuno TherapeuticsVerified email at cleyrat.com
Cédric CleyratJuno TherapeuticsVerified email at cleyrat.com